Results found (485)
February 5, 2013
Prepare your pita for the ultimate felafel

Hebrew University develops more nutritious chickpeas adapted to limited rainfall. Yissum, the university’s research and development company, has introduced new chickpea varieties that retain high nutritional values while showing improved...

January 2, 2013
Israeli Vets Formulate New Vaccine for Dogs

A serendipitous lab discovery led to a breakthrough vaccine for a fatal tick-borne disease. Now investors are sought to take it commercial

December 11, 2012
Yissum Introduces a Pioneering Vaccine Against Canine Monocytic...

Results showing the effectiveness of the vaccine in dogs were recently published in the journal Vaccine

November 25, 2012
The art of making a fortune by sharing royalties (Portuguese)
November 20, 2012
Yissum spin off Atox Bio reports positive tissue infection trial results

The company today reported positive results of the clinical trial of its drug for the treatment of necrotizing soft tissue infections.

November 15, 2012
New coating technique finds application in next-generation lithium battery...

When Ovadia Lev, Professor of Environmental Chemistry and Health at The Hebrew University of Jerusalem, and his research team developed a new coating technology a few years ago, they thought it was an interesting outcome of their research in...

November 13, 2012
Tiltan Pharma Announces Enrollment of First U.S. Patient in a Phase 2...

Tiltan Pharma is one of the portfolio companies of Integra Holdings, a biopharmaceutical holding company founded by Yissum, the technology transfer company of the Hebrew University of Jerusalem.

November 12, 2012
The mind's eye can learn to see, even in those blind since birth

The blind have long used other senses -- including touch -- to compensate for their visual impairment. But a new study finds that when images are conveyed as sound, even the congenitally blind can distinguish among objects and their brains...

October 31, 2012
Integra Holdings, a biopharmaceutical holding company, announced by Yissum

Integra Holdings closes U.S. $ 7.0 million private financing

October 5, 2012
Yissum's Atox Bio- A promising Orphan Drug Company (Hebrew)

One of six promising orphan Drugs currently under development in Israel, AB103 was granted Fast Track and Orphan Drug designations by the FDA.

September 10, 2012
FDA fast tracks Atox Bio’s tissue infections treatment

Drug developer Atox Bio announced today that the US Food and Drug Administration (FDA) has granted fast track designation to AB103, its lead product, currently in development for the treatment of Necrotizing Soft Tissue Infections (NSTI).

August 14, 2012
HIV Peptide Packs Cancer Treatment

Hebrew U. medical researchers find a tiny peptide encoded by the HIV virus could hold the key to making cancer therapies more successful.